| Biologic lung volume reduction therapy for advanced homogeneous emphysema. | |
| | |
MedLine Citation:
|
PMID: 19926742 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
This report summarises phase 2 trial results of biologic lung volume reduction (BioLVR) for treatment of advanced homogeneous emphysema. BioLVR therapy was administered bronchoscopically to 25 patients with homogeneous emphysema in an open-labelled study. Eight patients received low dose (LD) treatment with 10 mL per site at eight subsegments; 17 received high dose (HD) treatment with 20 mL per site at eight subsegments. Safety was assessed in terms of medical complications during 6-month follow-up. Efficacy was assessed in terms of change from baseline in gas trapping, spirometry, diffusing capacity, exercise capacity, dyspnoea and health-related quality of life. There were no deaths or serious medical complications during the study. A statistically significant reduction in gas trapping was observed at 3-month follow-up among HD patients, but not LD patients. At 6 months, changes from baseline in forced expiratory volume in 1 s (-8.0+/-13.93% versus +13.8+/-20.26%), forced vital capacity (-3.9+/-9.41% versus +9.0+/-13.01%), residual volume/total lung capacity ratio (-1.4+/-13.82% versus -5.4+/-12.14%), dyspnoea scores (-0.4+/-1.27 versus -0.8+/-0.73 units) and St George's Respiratory Questionnaire total domain scores (-4.9+/-8.3 U versus -12.2+/-12.38 units) were better with HD than with LD therapy. BioLVR therapy with 20 mL per site at eight subsegmental sites may be a safe and effective therapy in patients with advanced homogeneous emphysema. |
| | |
Authors:
|
Y Refaely; M Dransfield; M R Kramer; M Gotfried; W Leeds; G McLennan; S Tewari; M Krasna; G J Criner |
Publication Detail:
|
Type: Clinical Trial, Phase II; Journal Article Date: 2009-11-19 |
Journal Detail:
|
Title: The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology Volume: 36 ISSN: 1399-3003 ISO Abbreviation: Eur. Respir. J. Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-07-02 Completed Date: 2010-10-21 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8803460 Medline TA: Eur Respir J Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 20-7 Citation Subset: IM |
Affiliation:
|
Division of Cardiothoracic Surgery, Rabin Medical Center, Tel Aviv, Israel. Yaelre2@clalit.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Biological Therapy Bronchoscopy / methods* Dyspnea / surgery, therapy Exercise Female Fibrin Tissue Adhesive / therapeutic use* Follow-Up Studies Forced Expiratory Volume Humans Male Middle Aged Pneumonectomy / methods* Pulmonary Emphysema / drug therapy, surgery, therapy* Quality of Life Treatment Outcome Vital Capacity |
| Chemical | |
Reg. No./Substance:
|
0/Fibrin Tissue Adhesive |
| Comments/Corrections | |
Comment In:
|
Eur Respir J. 2010 Jul;36(1):8-9
[PMID:
20595161
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis.
Next Document: Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in CO...